Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics

Table 1 Baseline characteristics of all patients

	Group IA	Group IB	Group II	All patients
	n = 13 (37%)	n = 12 (34%)	n = 10 (29%)	n = 35 (100%)
Median age (range)	35 (21-48)	34 (20-45)	52 (42-68)	38 (20-68)
Male (%)	9 (69)	11 (92)	10 (100)	30 (86)
Chinese ethnicity (%)	13 (100)	11 (92)	10 (100)	34 (97)
Median (range) baseline ALT, U/L	28 (16-58)	136 (78-1 124)	87 (33-761)	74(16-1 124)
Median (range) baseline HBV DNA, Meg/mL	294 (120–1 680)	253 (38–616)	291 (20–786)	280 (20–1 680)
Median baseline CPT score	NA	NA	7.0 (5-13)	NA
Median (range) duration of lamivudine
at emergence of genotypic resistance, wk	160 (35-198)	110 (42-212)	62 (36-120)	143 (35-212)
Follow-up after genotypic resistance, wk	96 (48-220)	124 (26-208)	64 (34-102)	102 (26-220)
Number (%) with phenotypic resistance	3 (23)	9 (75)	6 (60)	18 (51)

Table 2 Comparison between patients with and without phenotypic resistance in univariate analysis

	Patients with phenotypic resistance n = 18	Patients without phenotypic resistance n = 17	P
Median (range) age (yr)	34 (21-60)	37(20-68)	0.95
Male (%)	17 (94)	13 (76)	0.16
Chinese (%)	17/18 (94)	17/17 (100)	0.28
Genotype (B:C:others)	7B/ 7C/ 2 others	11B /6C/ 2 others	0.56
Type of mutation (rtM204I:rtM204V:others)	12:2:4	4:10:3	0.074
Median (range) baseline ALT level, U/L	96 (42-1 124)	40 (16-143)	0.018
ALT level at emergence of genotypic resistance, U/L	48 (22-82)	36 (24-68)	0.36
Successful HBeAg seroconversion (%)	12	17.7	0.43
Median (range) baseline HBV DNA, Meq/mL	249 (20-788)	336 (20-1 680)	0.17
Median (range) peak HBV DNA after emergence of resistance, pg/mL	186 (8.8-1 064)	314 (9-3 920)	0.33
Median (range) duration of lamivudine at onset of resistance, wk	88 (35-212)	124 (36-202)	0.16
Median (range) duration of follow up after resistance, wk	124 (52-204)	102 (26-220)	0.29
Median (range) baseline CPT Score for cirrhotic patients, n = 10	(n = 6) 8 (5-13)	(n = 4) 7 (5-9)	0.038